Parabolic Drugs Limited. Parabolic Drugs Limited is a holding company. The Company is an integrated, research-based, pharmaceutical manufacturer and exporter, engaged in development and manufacturing of Active Pharmaceutical Ingredients (API) and API intermediates. It is engaged in the manufacture of pharmaceuticals, medicinal chemical and botanical products. Its products and services include Cefuroxime Axetil Amorphus and Ceftriaxone Sodium Sterile. Its product portfolio includes Oral and Sterile Semi Synthetic Penicillin API, Oral and Sterile Cephalosporin API in antibiotic segment to non-antibiotic API in the Cardiovascular, Nonsteroidal anti-inflammatory drugs (NSAID), Anti-Hypertensive and Osteoporosis segments. Its products include Cefixime Trihydrate, Ceftibuten, Cefcapene Pivoxil, Cefuroxime Sodium, Amoxycillin Trihydrate, Bacampicillin Hcl, Piperacillin Sodium, Sulbactum Sodium, Deferasirox, Pentazocine, Raubasine, Yohimbine, Montelukast, Vildagliptin, Cefoxitin Sodium and Cefpodoxime Acid.
Ford US Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.